Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Pulsed Perfusion for Marginal Kidneys (PREDICTION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02055950
Recruitment Status : Completed
First Posted : February 5, 2014
Last Update Posted : September 4, 2018
Sponsor:
Collaborator:
Policlinico San Matteo Pavia Fondazione IRCCS
Information provided by (Responsible Party):
Mario Negri Institute for Pharmacological Research

Brief Summary:
Trends in organ donor pool are characterized by an increasing age and a shift towards cerebrovascular diseases as primary causes of death. As a result, donors older than 60 years nowadays represent more than one fourth of the entire donor pool in Italy. This, along with an increasing number of patients on the waiting list for transplantation, prompted a growing use of organs from subjects older than 60 years that would have been considered unsuitable years ago. To improve graft outcomes, transplant of two older kidneys in the same recipient has been proposed. To optimize allocation of these organs to single or dual transplantation,a scoring system for kidneys, based on biopsy, with scores ranging from a minimum of 0 (indicating the absence of renal lesions) to a maximum of 12 (indicating the presence of marked changes in the renal parenchyma) has been suggested. According to this panel, kidneys with a score of 4 or lower are predicted to contain enough viable nephrons to be used as single transplants, those with a score of 5, 6, or 7 can be used as dual transplants, kidneys with a score greater than 7 are discarded. The survival of kidney grafts obtained from donors older than 60 years and allocated for single or dual transplantation on the basis of biopsy findings before transplantation was similar to that of single grafts from younger donors. To further improve these results, set-up of strategies to preserve organs is crucial to save the residual nephron mass and optimize outcomes of these marginal grafts. In this regard, over the past 30 years two methods of kidney preservation have been developed. With cold storage, the kidney is flushed once it is removed from the donor and placed in an ice-cooled container with preservation solution. With the use of pulsatile machine perfusion, the kidney is connected to a machine, which pumps a cold solution containing oxygen and nutrients through the kidney. This process allows for metabolism to continue in the kidney with end products being removed. The broad aim of the present study is to evaluate whether pulsatile machine perfusion of kidneys from older/marginal donors may provide better outcomes than static perfusion. To this purpose the outcome of recipients of perfused kidneys will be compared with the outcome of historical controls receiving non-perfused kidney selected and allocated on the basis of the same criteria and matched by gender, age and kidney histologic score.

Condition or disease Intervention/treatment
Chronic Kidney Disease Procedure: Storage of kidney in refrigerated solution Procedure: Kidney perfused by pulsatile machine

Layout table for study information
Study Type : Observational
Actual Enrollment : 60 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: A PROSPECTIVE STUDY TO COMPARE EARLY GRAFT FUNCTION OF RECIPIENTS OF SINGLE OR DUAL KIDNEY ORGANS STORED IN ICE COLD SOLUTION OR PULSED PERFUSION
Actual Study Start Date : July 2013
Actual Primary Completion Date : August 2018
Actual Study Completion Date : August 2018

Group/Cohort Intervention/treatment
Kidney perfused by pulsatile machine Procedure: Kidney perfused by pulsatile machine
Kidney stored in refrigerated solution Procedure: Storage of kidney in refrigerated solution



Primary Outcome Measures :
  1. Glomerular filtration rate (GFR) [ Time Frame: 6 months after transplant. ]
  2. Renal resistance [ Time Frame: 6 hours after pulsatile machine perfusion ]
    Renal resistance is measured by graft ultrasound. It ranges from 0 to 1.


Secondary Outcome Measures :
  1. Correlation between renal resistance measured at 6 hours after machine perfusion and renal histological score at pre-transplant biopsy [ Time Frame: 6 hours after pulsatile machine perfusion ]

    The severity of changes in kidney at pre-transplant biopsy was quantified by a predefined histologic score. Changes in each evaluated component of the kidney tissue , vessels, glomeruli, tubules, and connective tissue, received a score ranging from 0 to 3. The sum of these scores was defined as the global kidney score, which could range from 0 to 12.

    Renal resistance is measured by graft ultrasound. It ranges from 0 to 1.


  2. Correlation between renal resistances measured at 6 hours after pulsatile machine perfusion and intergraft resistances measured by ultrasound at 7 days and 6 months after transplant. [ Time Frame: Changes from 7 days at 6 months after transplant . ]
    Renal resistances are measured by graft ultrasound. They range from 0 to 1.

  3. Incidence of delayed graft function (DGF). [ Time Frame: Within the first week after transplant ]

Biospecimen Retention:   Samples Without DNA
Serum, urine.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who are eligible to receive a single or dual transplant from older/marginal deceased donors identified according to the Nord Italia Transplant criteria who consent to receive perfused with a pulsatile machine.
Criteria

Inclusion Criteria:

  • Males and females aged 50 years or more and no more than 10 years older or younger than their corresponding donors;
  • First single or double kidney transplant from deceased donors older than 60 years;
  • Pre-implantation histologic evaluation and graft selection and allocation based on the histologic score and according to the Nord Italian Transplant (NIT) criteria;
  • Written informed consent.

Exclusion Criteria:

  • Any factor that according to the NIT selection criteria represent a contraindication to receive a deceased donor kidney transplant
  • Need for specific de-sensitization protocols because of high immunological risk (according to NIT criteria) or participation in other concomitant intervention studies
  • Vascular abnormalities/changes that preclude the possibility to perfuse the kidney grafts by a pulsatile machine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02055950


Locations
Layout table for location information
Italy
A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/U.O. Chirurgia Pediatrica
Bergamo, Italy, 24100
IRCCS Policlinico S.Matteo - UOS trapianto di Rene/U.O. Nefrologia
Pavia, Italy, 27100
Sponsors and Collaborators
Mario Negri Institute for Pharmacological Research
Policlinico San Matteo Pavia Fondazione IRCCS
Investigators
Layout table for investigator information
Study Chair: Paolo Cravedi, MD IRCCS - Mario Negri Institute for Pharmacological Research
Principal Investigator: Giuseppe Remuzzi, MD IRCCS - istituto di Ricerche Farmacologiche Mario Negri - A.O. Papa Giovanni XXIII BG
Principal Investigator: Giovanni Rota, MD A.O. Papa Giovanni XXIII, Bergamo, Italy - U.O. Chirurgia Pediatrica
Principal Investigator: Salvatore De Pascale, MD A.O. Papa Giovanni XXIII, Bergamo, Italy - U.O. Chirurgia Pediatrica
Principal Investigator: Francesco La Canna, MD A.O. Papa Giovanni XXIII, Bergamo, Italy - U.O. Chirurgia Pediatrica
Principal Investigator: Giuseppe Piccolo, MD NIT (North Italian Transplant)
Principal Investigator: Giuseppe Rossini, MD NIT (North Italian Transplant)
Principal Investigator: Sergio Vesconi, MD NIT (North Italian Transplant)

Layout table for additonal information
Responsible Party: Mario Negri Institute for Pharmacological Research
ClinicalTrials.gov Identifier: NCT02055950    
Other Study ID Numbers: PREDICTION
First Posted: February 5, 2014    Key Record Dates
Last Update Posted: September 4, 2018
Last Verified: August 2018
Keywords provided by Mario Negri Institute for Pharmacological Research:
Kidney transplant
Marginal donors
Pulse perfusion
Graft function
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Pharmaceutical Solutions